News

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.

Based on their findings, an international team of researchers is discouraging the application of atropine as a standard therapy for trabeculectomy surgery.

Several strategies exist to improve safety of injections for patients.

Accurate publicly available information on the locations of paediatric ophthalmologists is warranted to increase access to care.

According to the company, it is planning to hold an end-of-phase 2 meeting with the FDA to discuss the results.

According to the company, it is planning an end-of-phase 2 meeting with the FDA to discuss the results.

The Phase 2 clinical trial will evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.

The PRPH2 and Associated Retinal Diseases Workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.

The intent of the award is to recognize early-career researchers who have exhibited excellence in research, as well as their fundamental scientific discoveries, concepts and novel technologies which have led to, or have the promise of leading to, clinical application.

A University of Houston researcher has been awarded a $1.6 million grant to help restore vision loss in patients with the rare disease that causes a progressive loss of vision, prompting retinitis pigmentosa.

A University of Houston researcher has been awarded a $1.6 million grant to help restore vision loss in patients with the rare disease that causes blindness.

The delivery of lipid nanoparticle-based mRNA to the retina is encouraging, according to researchers.

All events in the 2023 annual gathering, scheduled for February 2 to 4 in downtown San Francisco, California, will take place at a new venue, The Westin St Francis San Francisco on Union Square.

A team of researchers have found that STOC tomography enables unprecedented views of eye structure.

A team of researchers have found that STOC tomography enables unprecedented views of eye structure.

Company says the products will give its customers more choices and flexibility when considering treatment options for their patients and the specific needs of their practices.

The transaction between the 2 companies is expected to be completed in the first quarter of 2023.

After comparing two techniques of corneal transplant tissue preparation, research shows a newer, faster technique is safe and effective.

These awards will help to advance the winner’s work and research in their respective fields in retinal surgery and age-related macular degeneration (AMD).

The investigators set out to study if treatment of the tumours close to the optical pathway is safe and whether it may impair a patient’s vision.

Patient-tailored techniques result in predicable outcomes for patients.

Researchers used obesity as a model to accelerate and exaggerate the stressors experienced by the body throughout life.

According to the FTC, the money will be used to compensate consumers the company allegedly lured with deceptive offers.

The United States Department of Justice originally filed the lawsuit in December 2021 on behalf of an elderly quadriplegic patient, alleging that Tempe, Arizona-based Barnet Dulaney Perkins Eye Center was requiring patients with mobility disabilities to hire third-party medical transport and transfer assistance for outpatient surgical procedures. American Vision Partners was named as a codefendant.

The study advances the understanding of the leading cause of visual impairment in adults.

Coherus plans to file a Biologics License Application for FYB203 later in 2023 in preparation for an anticipated 2025 launch.